FDA approves Ryaltris nasal spray for seasonal allergic rhinitis
Click Here to Manage Email Alerts
The FDA approved olopatadine hydrochloride and mometasone furoate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and older, according to a press release.
Olopatadine hydrochloride and mometasone furoate (Ryaltris, Glenmark Pharmaceuticals) is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray. It contains 665 µg olopatadine hydrochloride, a histamine-1 receptor inhibitor, and 25 µg mometasone furoate, a corticosteroid.
“The FDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas,” Robert Crockart, chief commercial officer of Glenmark Pharmaceuticals, said in the press release. “With this [new drug application] approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms.”
The recommended daily dose of the nasal spray is two sprays in each nostril twice daily.